Tag: Cancer: Leukemia

Overall survival 64 and 55 percent at one and two years; nonrelapse mortality 20 and 28 percent, respectively

Inferior survival seen for children with acute lymphoblastic leukemia, but not acute myeloid leukemia, living on the border

The next-generation BTK inhibitor zanubrutinib showed greater progression-free survival and fewer side effects in phase 3 trial

Distinct mutational landscape and poorer outcomes seen for patients with MDS/acute myeloid leukemia versus MDS not otherwise specified

Inflammation-associated gene score identified in patients with acute myeloid leukemia, which is associated with poor survival outcomes

Time to antibiotics does not significantly affect overall survival at 180 days in patients with hematologic malignancy who develop inpatient neutropenic fever

Longer progression-free survival seen with zanubrutinib versus ibrutinib for patients with relapsed or refractory chronic or small lymphocytic leukemia

Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists

Multiparametric flow cytometry has excellent prediction for survival among patients with B-cell acute lymphoblastic leukemia

The 64th American Society of Hematology Annual Meeting and Exposition